GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NYSE:ADHD
Delisted

Alcobra Ltd. Fund Forecast

$1.46
+0 (+0%)
At Close: Jan 16, 2018
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

Alcobra Ltd. fund price ended at $1.46 on Tuesday, after losing 0%.
(Updated on Jan 16, 2018)

Buy or Hold candidate since Oct 12, 2017 Gain 24.79% PDF

No changes to the price of Alcobra Ltd. fund on the last trading day (Tuesday, 16th Jan 2018). During the last trading day the fund fluctuated 0% from a day low at $1.46 to a day high of $1.46. The price has been going up and down for this period, and there has been a 0% change for the last 2 weeks.

The fund is moving within a wide and horizontal trend and further movements within this trend can be expected. Given the current horizontal trend, you can expect Alcobra Ltd. fund with a 90% probability to be traded between $1.36 and $1.63 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and funds seldom manage to go directly from the bottom of a trend up to the top. Funds turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ADHD Signals & Forecast

The Alcobra Ltd. fund holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $1.46 and $1.45. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Monday, January 15, 2018, and so far it has fallen 0%. Further fall is indicated until a new bottom pivot has been found. Volume fell on the last day without any changes to the price. This does not cause any direct divergence but may be an early warning and a possible "turning point". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Alcobra Ltd. fund

Alcobra Ltd. finds support from accumulated volume at $1.44 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the fund tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the fund During the last day, the fund moved $0 between high and low, or 0%. For the last week the fund has had daily average volatility of 0%

Our recommended stop-loss: $1.40 (-4.00%) (This fund has low daily movements and this gives low risk. There is a sell signal from a pivot top found 1 day ago.)

Trading Expectations (ADHD) For The Upcoming Trading Day Of Wednesday 17th

For the upcoming trading day on Wednesday, 17th we expect Alcobra Ltd. to open at $1.46, and during the day (based on 14 day Average True Range), to move between $1.40 and $1.52, which gives a possible trading interval of +/-$0.0647 (+/-4.43%) up or down from last closing price. If Alcobra Ltd. takes out the full calculated possible swing range there will be an estimated 8.86% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $1.44 (1.37%) than the resistance at $1.49 (2.05%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Alcobra Ltd. fund A Buy?

Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Alcobra Ltd. fund to perform well in the short-term period.

Current score: 1.660 Buy Candidate Unchanged

Predicted Opening Price for Alcobra Ltd. of Wednesday, January 17, 2018

Fair opening price January 17, 2018 Current price
$1.46 ( 0%) $1.46

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ADHD

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 1.46 .
R2 1.46 .
R1 1.46 .
Current price: 1.46
Support S1 1.46 .
S2 1.46 .
S3 1.46 .

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 1.59 8.90 %
R2 1.51 3.42 %
R1 1.49 2.05 %
Current price 1.46
Support S1 1.44 -1.37%
S2 1.27 -13.01%
S3 1.23 -15.75%

FAQ

What is the symbol for Alcobra Ltd. Fund and on which exchange is it traded?
The symbol for Alcobra Ltd. is ADHD and it is traded on the NYSE (New York Stock Exchange).

Should I buy or sell Alcobra Ltd. Fund?
Several short-term signals are positive and we conclude that the current level may hold a buying opportunity, as there is a fair chance for Alcobra Ltd. fund to perform well in the short-term period.

How to buy Alcobra Ltd. Fund?
Alcobra Ltd. Fund can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Alcobra Ltd. Fund.

What's the current price of Alcobra Ltd. Fund?
As of the end of day on the 2018-01-16, the price of an Alcobra Ltd. (ADHD) share was $1.46.

What is the 52-week high and low for Alcobra Ltd. Fund?
The 52-week high for Alcobra Ltd. Fund is $2.17 and the 52-week low is $0.83.
Click to get the best stock tips daily for free!

About Alcobra Ltd.

Alcobra Ltd., a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company is primarily developing MDX (metadoxine), an onset/extended release formulation of the chemical pyridoxine pyroglutamate, which is in Phase III clinical trial for adults with attention deficit hyperactivity disorder (ADHD); in Phase II clinical trial for pediatric with ADHD; and which is completed Phase II clinical tria... ADHD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT